Advances in small-molecule therapy for managing angina pectoris in the elderly

Waheed, Nida; Mahmoud, Ahmad; Rambarat, Cecil A.; Pepine, Carl J.

doi:10.1080/14656566.2019.1615881

Cited by 2 publications

(1 citation statement)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, antianginal drugs such as nitrate ester preparations, β-receptor blockers, and calcium channel blockers are the first line for symptomatic management of angina pectoris in CHD [4]. There are certain limitations to the complicated disease of CHD angina pectoris, despite these drugs effectively relieving clinical symptoms [5]. In addition, a significant number of patients remain symptomatic despite the use of antianginal drugs [6].…”

Section: Introductionmentioning

confidence: 99%

Gualou Xiebai Guizhi Decoction in the Treatment of Angina Pectoris in Coronary Heart Disease: A Systematic Review and Meta-analysis

2024

medcm

View full text Add to dashboard Cite

The effectiveness of the Gualou Xiebai Guizhi Decoction (GLXBGZD) in treating angina pectoris associated with coronary heart disease (CHD), a prevalent cardiovascular condition, remains a topic of inquiry. Hence, this meta-analysis systematically evaluated its efficacy in this context. A comprehensive search spanning PubMed, Web of Science, Embase, SinoMed, WanFang Database, China National Knowledge Infrastructure, and Chinese Scientific Journal Database, from inception to November 2022, was conducted to identify studies investigating GLXBGZD combined with conventional antianginal drugs for CHD-related angina pectoris. Outcome measures encompassed clinical effectiveness rate, left ventricular ejection fraction, blood lipid levels, and angina pectoris duration and frequency. Meta-analysis was performed utilizing Stata17 and Review Manager 5.4 software. The study was registered in PROSPERO under the number CRD42022375760. Seven eligible studies involving 688 patients were included. Compared to conventional treatments, GLXBGZD combined with conventional treatments exhibited a significant improvement in the clinical efficacy rate (odds ratio, 3.90; 95% confidence interval, 2.21-6.86; P <0.001). Furthermore, GLXBGZD combined with conventional treatments showed promising trends in enhancing heart function and blood lipid profiles (including reductions in total cholesterol, triglyceride, and low-density lipoprotein levels, along with an increase in high-density lipoprotein levels), as well as in reducing the duration and frequency of angina. However, we did not reach statistical significance for these outcomes (all P >0.05). In conclusion, the combination of GLXBGZD with conventional treatment demonstrated an enhanced clinical efficacy in the management of CHD-related angina pectoris. Nevertheless, there remains insufficient evidence to conclusively establish the benefits of GLXBGZD combined with conventional treatment in improving blood lipid levels and cardiac function, as well as in reducing the duration and frequency of angina pectoris.

show abstract

Section: Introductionmentioning

confidence: 99%